Be Familiar With the Latest Monoclonal Antibody to Treat COVID-19
Casirivimab/imdevimab will be the second monoclonal antibody authorized to treat OUTpatients with COVID-19.
This combo will be an alternative to bamlanivimab as a single-dose IV infusion. And more are in the works.
These "mabs" block the virus that causes COVID-19...SARS-CoV-2...from entering cells. And combo products may reduce the chance of developing resistant viral variants.